How have FDA priorities changed from 2019 to 2020?

2 December 2019

The Food and Drug Administration (FDA), under the strong leadership of Commissioner Dr Scott Gottlieb, moved into 2019 with a clear direction to address its most urgent priorities. Despite Dr Gottlieb’s unexpected resignation in March 2019 1 and the subsequent appointment of two further acting Commissioners throughout the course of the year, several key FDA achievements were realized. Dr Nicola Davies investigates these achievements and the FDA’s focus for 2020 in her exclusive column for The Pharma Letter.

Meeting 2019 priorities:

Increase in generic approvals

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK